Beyond the statistical success of the device, clinical data indicates tangible improvements in patient quality of life. Participants reported meaningful gains in daily function and physical mobility throughout the observation period. These findings validate the company's current path as it continues to monitor the long-term performance of the stent.

While the primary endpoint has been met, the study remains active. Becton Dickinson confirmed that clinical follow-up for the iliac cohort will continue through the 36-month mark. This extended tracking will provide further evidence regarding the long-term durability and safety profile of the Revello system as the company weighs future regulatory steps.